Swedish Orphan Biovitrum AB (publ) is an international specialty biopharmaceutical company headquartered in Stockholm, Sweden, focused on developing and commercializing treatments for rare diseases in... Swedish Orphan Biovitrum AB (publ) is an international specialty biopharmaceutical company headquartered in Stockholm, Sweden, focused on developing and commercializing treatments for rare diseases in haematology, immunology, and specialty care. The company specializes in orphan drugs, addressing unmet medical needs in areas such as haemophilia, immune thrombocytopenia (ITP), cryopyrin-associated periodic syndromes (CAPS), respiratory syncytial virus (RSV) prevention, and hemophagocytic lymphohistiocytosis (HLH). Key products include Elocta and Alprolix for haemophilia, Doptelet for ITP and chronic liver disease, Kineret for autoinflammatory disorders, Synagis for RSV, and Gamifant for primary HLH. Swedish Orphan Biovitrum AB also manages a pipeline of investigational therapies targeting paroxysmal nocturnal hemoglobinuria (PNH), secondary HLH, acute graft failure, ALS, chronic refractory gout, and recently added pozdeutinurad (AR882) through the acquisition of Arthrosi Therapeutics. Originating from mergers in the early 2000s and the 2010 acquisition of Swedish Orphan International, the company has grown significantly, employing around 1,500 people and generating substantial revenues by supporting patients with specialized therapies worldwide.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

Energy Management data not yet covered for Swedish Orphan Biovitrum

We have not yet reviewed Swedish Orphan Biovitrum's disclosures for Energy Management data.

If this data is relevant to your work, you can submit a data coverage request and our team will investigate the company's disclosures and capture the data if available.

Would you like us to review Swedish Orphan Biovitrum's data?

Start your 30-day free trial to request a data review for Swedish Orphan Biovitrum.

Start Free Trial

Legal Center Contact Us